We're Supporting COVID-19 Research
In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact email@example.com to learn more about this program.
From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!
Our Latest COVID-19 Research News
Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants
Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
Prominent biotech leaders release Covid-19 guidelines calling for FDA independence, data transparency
HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients
Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?